Ranka Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 1.50 M
- Company Age 39 Year, 19 Days
- Last Filing with ROC 31 Mar 2009
- Satisfied Charges ₹ 2.05 Cr
About Ranka Pharmaceuticals
Company Details
-
Location
Chennai, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24231TN1986PTC012603
-
Company No.
012603
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
27 Jan 1986
-
Date of AGM
28 Sep 2009
-
Date of Balance Sheet
31 Mar 2009
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Ranka Pharmaceuticals?
Board Members (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Dhirajmal Gautam
![]() |
Director | 27-Jan-1986 | Current |
Mangala Ranka
![]() |
Director | 27-Jan-1986 | Current |
Financial Performance of Ranka Pharmaceuticals.
Enhance accessibility to Ranka Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
![Graph illustrating revenue growth over time](/Images/financial/revenue-growth.webp)
![Graph showing profit and loss trends over time](/Images/financial/profit-loss.webp)
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
|
||||||
Revenue from Operations |
|
||||||
Total Assets |
|
||||||
Profit or Loss |
|
||||||
Net Worth |
|
||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Ranka Pharmaceuticals?
Unlock access to Ranka Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
![Shareholding Indicator graph](/Images/tcc-login/Shareholding-Indiacator-1200.webp)
Charges (Loans)
₹0
₹20.46 M
Charges Breakdown by Lending Institutions
- Indian Bank : 0.90 Cr
- Oriental Bank Of Commerce : 0.75 Cr
- State Bank Of India : 0.40 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
20 Dec 1993 | Oriental Bank Of Commerce | ₹7.50 M | Satisfied |
25 Aug 1990 | Indian Bank | ₹8.96 M | Satisfied |
24 Jul 1987 | State Bank Of India | ₹1.00 M | Satisfied |
23 Feb 1987 | State Bank Of India | ₹3.00 M | Satisfied |
How Many Employees Work at Ranka Pharmaceuticals?
Unlock and access historical data on people associated with Ranka Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
![Graph showing employee growth trends](/Images/tcc-login/Employee-Graph.webp)
Deals i
![Graph showing company valuation over time](/Images/tcc-login/Valuation-Graph-small.webp)
Gain comprehensive insights into the Deals and Valuation data of Ranka Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ranka Pharmaceuticals's trajectory.
Rating
![Graph displaying rating trends over time](/Images/tcc-login/Rating-Graph-small.webp)
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
![Alert Indicator](/Images/tcc-login/Alert-Indicator-small.webp)
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.